4565 Sosei Group Corporation

Sosei Heptares Webinar Presentation for Q2 FY2022 Financial Results

Sosei Heptares Webinar Presentation for Q2 FY2022 Financial Results

TOKYO, Japan and CAMBRIDGE, United Kingdom, July 11, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) will announce its earnings results and present operational highlights for the 6 months ended 30 June 2022 on Wednesday, 10 August 2022.

The Company will host a webinar presentation with Chris Cargill, President and CEO, Matt Barnes, President of Heptares Therapeutics and Head of UK R&D, and Hironoshin Nomura, CFO, at 5 pm JST (9 am BST) on Wednesday, 10 August 2022.

The webinar is open to all existing and potential investors as well as sell-/buy-side analysts and will consist of a presentation followed by a Q&A session. Please click to pre-register, which will provide a link to access the webinar.

Presentation slides will be made available by 4 pm JST (8 am BST) on the 10 August 2022 through the investor section of the Company’s Home Page .

Enquiries:

Sosei Heptares – Media and Investor Relations

Hironoshin Nomura, Chief Financial Officer

Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures

Candelle Chong, SVP Investor Relations and Corporate Strategy

Japan: +81 (0)3 5210 3399 | United Kingdom: +44 (0)1223 949390 |

MEDiSTRAVA Consulting (for International Media)

Mark Swallow, Frazer Hall, Eleanor Perkin

+44 (0)203 928 6900 |

 



EN
11/07/2022

Underlying

4565Sosei Group Corporation

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sosei Group Corporation

 PRESS RELEASE
Free
4565 Sosei Group Cor...

Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Foll...

Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568 Tokyo, Japan and Cambridge, UK, 3 June 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner, Neurocrine Biosciences (“Neurocrine”) has dosed the first patient in its Phase 3 registrational program of NBI-1117568 (NBI-’568) as a potential treatment for schizophrenia, resulting in a payment of US$15 million to Nxera (Clinical Trial ID: ). The US$15 million payment will be fully recognized as revenue in the second qua...

June 2, 2025 1 EN
 PRESS RELEASE
Free
4565 Sosei Group Cor...

Nxera Pharma Achieves Development Milestone in Collaboration with Eli ...

Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases Tokyo, Japan and Cambridge, UK, 2 June 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly and Company (“Lilly”) targeting diabetes and metabolic diseases, resulting in a payment to Nxera. The payment amount is undisclosed under the agreement with Lilly. However, Nxera makes this announcement in accordance with the timely disclosure requir...

June 1, 2025 1 EN
 PRESS RELEASE
Free
4565 Sosei Group Cor...

Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data f...

Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 Tokyo, Japan and Cambridge, UK, 29 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes that Neurocrine Biosciences, Inc. announced that it had presented new positive data from the Phase 2 study of NBI-1117568 in adults with schizophrenia at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting in Scottsdale, Arizona. For more information, please read Neuro...

May 28, 2025 1 EN
 PRESS RELEASE
Free
4565 Sosei Group Cor...

Nxera Pharma Operational Highlights and Consolidated Results for the F...

Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025 Tokyo, Japan and Cambridge, UK, 2 May 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2025. The full report can be found . Chris Cargill, President and CEO of Nxera, commented: “As we mark one year since our transformation from Sosei Heptares to Nxera Pharma, I am incredibly proud of the progress we’ve made and how we have evolved. Our new identity has unified the Group and h...

May 2, 2025 1 EN
 PRESS RELEASE
Free
4565 Sosei Group Cor...

Nxera Pharma’s Partner Neurocrine Biosciences Initiates Phase 3 Regist...

Nxera Pharma’s Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with NeurocrineFor more information, please read Neurocrine’s announcement () Tokyo, Japan and Cambridge, UK, 1 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has initiated a Phas...

April 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch